The prospect of finding answers to such questions is leading pharmaceutical companies and academic researchers to seek collaborations with Lancaster and Jürgen Knoblich, whose lab at the Institute of Molecular Biotechnology (IMBA) in Vienna, Austria, is where Lancaster developed the organoids as a postdoc.